There’s a lot of money moving through the peptide space right now. Private equity is paying attention, strategic acquirers are circling, and founders who built something real are starting to get calls.
The M&A activity is also real. Early in 2025, AbbVie acquired Nimple Therapeutics for $288M. Teledoc company, Hims & Hers Health, acquired a US-based peptide facility for an undisclosed amount. And in September of 2025, Pfizer dropped $10B on Metsera, specifically to deepen their GLP-1 bench. In the peptide world, the regulatory winds are shifting. The FDA is moving to reclassify 12 previously banned peptides and is scheduled to hold advisory committee meetings in July 2026 to discuss returning several compounds to legal status. All of this is only expected to increase M&A activity into late 2026 and beyond.
So here’s the question I want to ask every peptide operator right now. When someone comes knocking and asks to see your books, are they actually ready?
Because the thing is “Clean books” and “audit-ready books” are not the same thing. Confusing the two can dramatically slow down an M&A transaction. And if there’s anything I’ve learned over the years, it’s that time kills all deals.
Accurate to the Penny, And Still Not Enough
Let me explain what I mean. A well-run company with a good accountant probably has monthly financials that are solid, with revenue recognized, expenses categorized and the balance sheet tied out.
But here’s the trap. An audit isn’t primarily about whether your numbers are correct. An audit is about whether an independent examiner can verify that your numbers are correct, using documents that exist outside your own books. That’s a very different standard.
When an auditor sits down with your financials, they’re going to want to agree every material balance to something external. Bank statements, vendor invoices, signed contracts, purchase orders, receiving logs, certificates of analysis and credit card receipts, to name a few. They’re not taking your word for it, even if your word is completely accurate. Their job is to build an evidence trail, and if that trail doesn’t exist, the number doesn’t exist, at least not for their purposes.
Let me repeat that again, because it’s important. By audit standards, if a number cannot be supported it is not reportable (even if it is correct).
This is what people mean by “audit standard.” And it has a lot more to do with documentation than it does with accuracy alone.
Think of it like this. If I told you I ran a 5K in 22 minutes, you might believe me. But if you asked me to prove it for an official race result, I’d need a timing chip, a bib number, and a verified finish line crossing. The time might be exactly right. But without the documentation, it doesn’t count.
Your books work the same way in a transaction.
Why Peptides Make This Harder
Honestly, this is a challenge in a lot of industries. But peptides have a specific set of problems that make the documentation gap worse than most.
Start with inventory. In a typical business, your inventory is what it is. You bought it, it sits on the shelf, you sell it. But in the peptide space, the value of your raw material can change based on a single regulatory announcement. We’ve watched compounds go from legal to prohibited and back again inside the same 18-month window. If you’re sitting on inventory that was banned and then came back, do you have documentation showing how you handled that write-down, the disposition of the material, and how you rebooked it when the rules changed? Most businesses don’t, because it didn’t feel like a paperwork moment. It was a survival moment.
Then there’s the payment processing issue. Because peptide businesses often operate in a regulatory gray zone, merchant processors hold reserves sometimes 10% to 12% of card sales, locked up for 90 to 180 days before releasing them. If your accountant has been booking those reserves as available cash, your balance sheet looks healthier than it actually is. An auditor is going to want to reconcile every merchant account to actual available balances. That reconciliation needs documentation going back years in some cases.
Revenue recognition is another one. If you’re running subscription-based wellness programs, you may be selling bundles that include product, consultations, and ongoing care in a single transaction. The accounting rule, ASC 606, requires you to allocate the transaction price across each separate deliverable and recognize revenue as each piece is delivered. If your accountant has been booking the full payment on day one, the adjustment isn’t just an audit finding. It can materially restate your revenue over multiple periods. That’s a rough conversation to have mid-deal.
And supply chain documentation is its own minefield. A significant portion of peptide raw material comes from overseas suppliers, with U.S. purchases from Chinese sources approaching $328 million in the first nine months of 2025 alone. An auditor is going to want certificates of analysis, supplier qualifications, and chain-of-custody documentation for every significant purchase. If you’ve been buying from a supplier you trust without maintaining a full documentation file, that’s a gap that takes time to close and you can’t backfill it overnight.
“Audit Ready” Takes Longer Than You Think
This is the part I really want operators to hear. Getting a set of peptide books from “good” to “audit ready” is not a two-week project. In many cases, it takes three to six months of dedicated work, sometimes longer. And it is expensive.
Here’s what that work actually involves. A skilled team needs to go back through prior periods and build the supporting documentation files that tie each reported balance to an external source. That means pulling bank statements and reconciling them to the books month by month, and locating vendor invoices and matching them to payables. It also means documenting how you’ve valued inventory, and supporting those valuations with cost records and any impairments taken. It means reviewing revenue recognition and making sure the method you’ve been using holds up under scrutiny.
In the peptide space specifically, it also means dealing with a regulatory history such as, FDA guidance changes, inventory write-downs and merchant reserve accounting, that most businesses never documented in real time. These weren’t tidy bookkeeping moments when they happened. Reconstructing the financial trail is painstaking work.
None of this means your books were wrong. It just means they weren’t built for external examination. And in a deal, external examination can cut your due diligence timeline in half.
The Other Side of the Table
I’ve been focused on operators so far but this matters equally if you’re an investor or acquirer looking at peptide targets.
You need someone who knows what they’re looking for in this specific space. A general-purpose financial due diligence team will find the obvious things. But the nuanced risks (merchant reserve misclassification, inventory that’s been through a regulatory disruption, revenue bundles that haven’t been properly allocated, supply chain documentation gaps from overseas sourcing) require someone who understands how this industry actually operates.
Audits in new and emerging markets are valuable. They protect you, give you a number you can stand behind post-close and surface risks before they become your risks. But only if the person reviewing the books knows where to look.
So Where Does This Leave You?
If you’re an operator, the honest answer is to get your books evaluated now, not for accuracy, but for auditability. Find out where your documentation gaps are while you still have time to close them on your own terms.
If you’re an investor, build the cost of audit-readiness work into your deal thesis on any peptide target. It’s not a red flag if the books need work. It’s just part of what you’re buying in a fast-moving emerging market. The question is whether someone on your team can quantify it.
Either way, this is the kind of work that looks boring until it isn’t. The deals that fall apart at the finish line, or close at a number no one expected, almost always trace back to something that started in the books. Not inaccurate books, just books that were never built to survive outside scrutiny.
That’s exactly the kind of work we do at High Rock. We understand the peptide space, we know where the documentation gaps live, and we can help both operators and acquirers figure out exactly where they stand. Reach out to our team today.
Enjoyed this article? Consider Sharing
Author
